Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Cardiovascular disease in Noonan syndrome

Pierpont, Mary Ellaa,b; Digilio, Maria Cristinac

doi: 10.1097/MOP.0000000000000669
CARDIOVASCULAR MEDICINE: Edited by Daniel Bernstein

Purpose of review To provide information on the scope of cardiac disease in Noonan syndrome.

Recent findings Noonan syndrome is a common autosomal dominant RASopathy disorder characterized by clinical findings of facial dysmorphism, congenital heart disease, and short stature. The degree of genetic heterogeneity has recently become evident in that Noonan syndrome is now known to be caused by mutations in a large variety of genes which produce dysregulation of the RAS–MAPK (mitogen-activated protein kinase) signaling pathway. The scope of cardiac disease in Noonan syndrome is quite variable depending on the gene mutation, with some mutations usually associated with a high incidence of congenital heart defects (PTPN11, KRAS, and others) while those with predominantly hypertrophic cardiomyopathy (HCM) have higher risk and morbidity profiles (RAF1, RIT1, and those associated with multiple lentigines).

Summary Cardiac disease in Noonan syndrome varies according to the type of gene mutation. The most common forms of cardiac disease include pulmonary stenosis, HCM, and atrial septal defect. HCM in general is associated with increased risk, mortality, and morbidity. New concepts for potential treatments are discussed.

aDepartment of Pediatrics, University of Minnesota

bCardiovascular Research, Children's Hospital of Minnesota, Minneapolis, Minnesota, USA

cMedical Genetics, Bambino Gesù Children's Hospital, Rome, Italy

Correspondence to Mary Ella Pierpont, MD, PhD, Department of Pediatrics, University of Minnesota, 2450 Riverside Avenue, Minneapolis, MN 55454, USA. Tel: +1 612 626 9784; fax: +1 612 625 0500; e-mail: pierp001@umn.edu

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.